Swiggy Q2 Results: Net Loss Narrows But Misses Estimates, Revenue Rises 36%
Swiggy moved higher in a quarterly results development.
· NDTV Profit, BS Companies
Revenue from operations rose 36.1% to Rs 7,571 crore from Rs 5,561 crore the previous year, exceeding the Bloomberg estimate of Rs 7,336 crore.
The analysis
Swiggy reported Rs 7,571 crore, Rs 5,561 crore and Rs 7,336 crore, with movement of 36% and 36.1% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -4.7% on the day at ₹176.60, and has returned -40.3% over three months. It sits 58% below its 52-week high, which means a good deal of bad news was already in the price. The hotels & restaurants sector has moved -0.9% over the same period, so Swiggy is running 39.4 points behind its peers.
For Swiggy, the question is how much of this is already reflected in the price and how much re-rates the hotels & restaurants peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Swiggy (SWIGGY), in Hotels & Restaurants.
- Over three months: Swiggy -40.3% against Hotels & Restaurants -0.9% (39.4 points behind).
- At least 25% below the 52-week high: Swiggy (58%).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| SwiggySWIGGY · Hotels & Restaurants | ₹176.60 | -4.7% | -29.4% | -40.3% | -57.7% | 1.5× | — |
Hotels & Restaurants
1M -3.1% · 3M -0.9%
Swiggy
Prices as of 30 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Mid Smallcaps under pressure; Suzlon, Swiggy, STL, HFCL slip up to 10%
Swiggy block deal: Rs 982 crore worth shares change hands; key details
Meesho Q2 Results: Loss narrows to Rs 132 crore YoY, revenue rises 34%
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Why is VBL down 5% despite Q3 PAT jumps on double-digit volume growth?